Amy Hatok
Medical · Newport News, VANPI 1770593576
Payments from drug & device makers
Across 130 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$466
- Novo Nordisk$245
- Axsome Therapeutics, Inc.$217
- AstraZeneca$213
- Lilly USA, LLC$198
- Pfizer$195
- plus $942 from 22 others
What the payments were for
- Food & beverage$2,477100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $466 |
| Novo Nordisk | 14 | $245 |
| Axsome Therapeutics, Inc. | 10 | $217 |
| AstraZeneca | 7 | $213 |
| Lilly USA, LLC | 10 | $198 |
| Pfizer | 11 | $195 |
| Johnson & Johnson | 13 | $192 |
| Astellas Pharma US Inc | 8 | $142 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $84 |
| Sumitomo Pharma America, Inc. | 4 | $78 |
| Biohaven Pharmaceuticals, Inc. | 2 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Shield Therapeutics Inc | 2 | $42 |
| Abbott | 2 | $40 |
| Stryker | 1 | $32 |
| Biogen | 2 | $31 |
| Antares Pharma, Inc. | 2 | $27 |
| Tactile Systems Technology Inc | 1 | $24 |
| Myovant Sciences Inc. | 1 | $21 |
| Amgen | 1 | $19 |
| Innovation Technologies Inc | 1 | $19 |
| Agile Therapeutics, Inc. | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Merck | 1 | $15 |
| Coopersurgical, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,477 in reported general payments places this provider in the 75th percentile of 632 medical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 30 | $52,652 |
| EliquisApixaban | 41 | $45,928 |
| TrulicityDulaglutide | 12 | $24,881 |
| XareltoRivaroxaban | 20 | $19,628 |
| FarxigaDapagliflozin Propanediol | 15 | $17,966 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $16,441 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,451 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $4,004 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,168 |
| Atorvastatin Calcium | 231 | $1,943 |
| SynthroidLevothyroxine Sodium | 32 | $1,794 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,582 |
| Esomeprazole Magnesium | 15 | $1,520 |
| Amlodipine Besylate | 191 | $1,307 |
| Levothyroxine Sodium | 130 | $1,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $245 | $52,65230 claims |
| PfizerEliquis | $195 | $45,92841 claims |
| Lilly USA, LLCTrulicity | $198 | $24,88112 claims |
| Johnson & JohnsonXarelto | $192 | $19,62820 claims |
| AstraZenecaFarxiga | $213 | $17,96615 claims |
| GSKTrelegy Ellipta | $12 | $10,45114 claims |
| AbbVieSynthroid | $466 | $1,79432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 632 medical providers in Virginia.
Other medical in Newport News
- Philip GureckiNewport News$13K
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$51K
- Christine KesslerKing George$20K
- Janlyn AnthonyRichmond$18K
- Cara DepanfilisNorfolk$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.